| Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. | |
| | |
MedLine Citation:
|
PMID: 21467232 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the occurrence of HCC has more than doubled in the United States in the past decade. Early detection is considered key to reducing the mortality of HCC. METHODS: Using two-dimensional gel electrophoresis and high-performance liquid chromatography we have analyzed the glycosylation of Apo-J from healthy controls, patients with liver cirrhosis, or those with HCC. RESULTS: Apo-J in the serum from patients with HCC had decreased levels of (β-1,4) triantennary N-linked glycan compared with the healthy controls or patients with liver cirrhosis. We analyzed this change in an independent cohort of 76 patients with HCC, 32 with cirrhosis, and 43 infected with hepatitis C virus using the Datura stramonium lectin (DSL), which binds to (β-1,4) triantennary N-linked glycan. The level of DSL-reactive Apo-J allowed us to differentiate HCC from cirrhosis with an area under the receiver operating characteristic curve (AUROC) of 0.852. When Apo-J was combined with other serum biomarkers such as α-fetoprotein (AFP) and fucosylated kininogen by using a multivariate logistic regression model, the AUROC increased to 0.944, a value much greater than that observed with AFP alone (AUROC of 0.765). CONCLUSIONS: The glycosylation of Apo-J is a useful marker when used alone or in combination with outer makers for the early detection of HCC. IMPACT: The potential use of a combination of AFP, DSL-reactive Apo-J, and fucosylated kininogen as a biomarker of HCC would have great value in the management of patients with liver disease. |
| | |
Authors:
|
Mary Ann Comunale; Mengjun Wang; Lucy Rodemich-Betesh; Julie Hafner; Anne Lamontagne; Andrew Klein; Jorge Marrero; Adrian M Di Bisceglie; Robert Gish; Timothy Block; Anand Mehta |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2011-04-05 |
Journal Detail:
|
Title: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Volume: 20 ISSN: 1538-7755 ISO Abbreviation: Cancer Epidemiol. Biomarkers Prev. Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-09 Completed Date: 2011-09-30 Revised Date: 2012-03-16 |
Medline Journal Info:
|
Nlm Unique ID: 9200608 Medline TA: Cancer Epidemiol Biomarkers Prev Country: United States |
Other Details:
|
Languages: eng Pagination: 1222-9 Citation Subset: IM |
Copyright Information:
|
©2011 AACR. |
Affiliation:
|
Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virus Research, Drexel University College of Medicine, Doylestown, Pennsylvania 18902, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoma, Hepatocellular
/
blood,
diagnosis* Case-Control Studies Chromatography, Liquid Clusterin / blood* Electrophoresis, Gel, Two-Dimensional Female Glycosylation Humans Liver Cirrhosis / blood, diagnosis* Liver Neoplasms / blood, diagnosis* Male Middle Aged Neoplasm Staging Polysaccharides / analysis ROC Curve Risk Factors Tandem Mass Spectrometry Tumor Markers, Biological / blood* alpha-Fetoproteins / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA120206/CA/NCI NIH HHS; R01 CA136607/CA/NCI NIH HHS; R01 CA136607-04/CA/NCI NIH HHS; U01 CA084951-10/CA/NCI NIH HHS; UO1 CA084951/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/CLU protein, human; 0/Clusterin; 0/Polysaccharides; 0/Tumor Markers, Biological; 0/alpha-Fetoproteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of Aerobic Exercise on Premenopausal Sex Hormone Levels: Results of the WISER Study, A Rando...
Next Document: Inflammation-related gene variants as risk factors for pancreatic cancer.